Direct-to-Consumer Advertising
Letters
| May 20, 2008 |
Letter to the CEOs of five companies regarding direct-to-consumer advertising
Johnson & Johnson »
response »
Merck & Co., Inc. »
Pfizer, Inc. »
Pharmaceutical Research and
Manufacturers of America »
Schering-Plough Corporation »
May 30, 2008 response »
|
| April 25, 2008 |
Letter FDA Commissioner von Eschenbach in regard to misleading statements in direct-to-consumer advertisements of prescription medications
May 15, 2008 response »
|
| March 31, 2008 |
Letters to Johnson & Johnson and Amgen Inc., requesting documents relating to the marketing strategies of a class of drugs known as Erythropoiesis-Stimulating Agents (ESAs)
read the Johnson & Johnson Letter »
read the Amgen Inc., Letter » |
| Feb. 11, 2008 |
Letter to Softlayer Technologies, Inc. and Cafepharma Inc. requesting information about messages posted to the Web site Cafepharma.com |
| Feb. 11, 2008 |
Letter to Schering-Plough Corporation and Merck and Co., Inc. requesting information about messages posted to the Web site Cafepharma.com |
| Feb. 11, 2008 |
Letter to Schering-Plough Corporation and Merck and Co., Inc. requesting further data relating to a timeline of the study released by the companies
April 9, 2008 response »
March 31, 2008 response »
March 24, 2008 response » |
| Feb. 11, 2008 |
Letter to FDA Commissioner von Eschenbach in regard to the delay in releasing the ENHANCE clinical trial study results
March 5, 2008 response » |
| Feb. 6, 2008 |
Letters to 10 organizations involved in advertisements for Pfizer's Lipitor featuring Dr. Robert Jarvik |
| Jan. 24, 2008 |
Letter to American College of Cardiology CEO Lewin in regard to the withholding of clinical data during the ENHANCE trial |
| Jan. 24, 2008 |
Letter to American Heart Association CEO Wheeler in regard to the withholding of clinical data during the ENHANCE trial |
| Jan. 24, 2008 |
Letter to Schering-Plough Corporation and Merck & Co., Inc. in regard to the withholding of clinical data during the ENHANCE trial |
| Jan. 22, 2008 |
Letter to FDA Commissioner von Eschenbach in regard to the Committee's ongoing investigation into Vytorin and the ENHANCE trial
January 25, 2008 response » |
| Jan. 22, 2008 |
Letter to Health and Human Services in regard to the Committee's ongoing investigation into Vytorin and the ENHANCE trial
February 14, 2008 response » |
| Jan. 22, 2008 |
Letter to Schering-Plough Corporation and Merck and Co., Inc. in regard to the Committee's ongoing investigation into Vytorin and the ENHANCE trial |
| Jan. 16, 2008 |
Letter to Schering-Plough Corporation and Merck and Co., Inc. in regard to concerns about misleading statements in Direct-to-Consumer advertisements of prescription drugs |
| Jan. 16, 2008 |
Letter to FDA Commissioner von Eschenbach in regard to concerns about misleading statements in Direct-to-Consumer advertisements of prescription drugs
February 28, 2008 response »
February 1, 2008 response » |
| Jan. 7, 2008 |
Letter to Pfizer, Inc. Chairman of the Board and CEO Kindler in regard to concerns about celebrity endorsements of prescription medications in direct-to-consumer advertising
April 28, 2008 response »
February 25, 2008 response » |
News Releases
"Dingell, Stupak Request Improved Accuracy, Stronger Guidelines for DTC Ads" -- May 20, 2008
"Dingell, Stupak Comment on Pfizer Decision to Pull Lipitor Ads Featuring Dr. Jarvik" -- February 25, 2008
"Continues Investigation into Celebrity Drug Endorsements" -- February 7, 2008
"Dingell, Stupak Question Merck/Schering-Plough’s Sponsorship of American College of Cardiology and American Heart Association" -- January 24, 2008
"Dingell, Stupak Comment on Decision to Pull Vytorin Ads" -- January 23, 2008
"Dingell, Stupak to Continue ENHANCE Trial Investigation" -- January 18, 2008
"Committee Opens Investigation into Celebrity Drug Endorsements" -- January 7, 2008
|
